TREMOR IN CHARCOT-MARIE-TOOTH

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorUniversity Medical Center Goettingen

About this trial

Tremor is a symptom that has already been described in many case reports and case series concerning patients with Charcot-Marie-Tooth (CMT) disease. However, the pathophysiology of tremor in this condition remains largely unclear. It has also not been sufficiently investigated to what extent tremor in CMT patients constitutes a relevant impairment of quality of life.

This project focuses on a more detailed characterization of tremor in CMT patients using surface electromyography and accelerometer analysis, as well as the collection of individual clinical data, particularly regarding the symptom of tremor, in order to facilitate the characterization and etiological classification of the tremor. In addition, a questionnaire-based assessment will be conducted to capture the impact of tremor on activities of daily living and the associated burden in this specific patient cohort.

The entire data collection process will be supported by a clinical examination, which will be video-recorded by experienced neurologists to ensure more reliable analysis. This serves both the characterization of tremor and the illustration of its functional limitations. Where available, the data will be correlated with genetic variants to allow conclusions about possible genetic predispositions or disease progression. As a control group, CMT patients who have not yet reported a tremor will be included.

Eligibility criteria

Qualifiers

Clinical CMT Diagnosis / Anamnestically Healthy Control Group

Genetic confirmation of CMT in adult patients

Ability to achieve the outcome measure at baseline

Age between 18 and 65 years

Disqualifiers

Pregnancy or breastfeeding period

Other relevant neurological or psychiatric disorders, acute or in the past history

Presence of a serious previous internal disease

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

75 Participants
are grouped into 2 trial groups